Predictors of Sustained Intraocular Pressure Elevation in Eyes Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Therapy

被引:36
作者
Yannuzzi, Nicolas A. [1 ,2 ]
Patel, Samir N. [1 ,2 ]
Bhavsar, Kavita V. [2 ,3 ,4 ]
Sugiguchi, Fumitaka [1 ,2 ]
Freund, K. Bailey [2 ,3 ,4 ]
机构
[1] Weill Cornell Med Coll, New York, NY USA
[2] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY USA
[3] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA
[4] NYU, Sch Med, Dept Ophthalmol, New York, NY USA
关键词
MACULAR DEGENERATION; REPACKAGED BEVACIZUMAB; FACTOR AGENTS; INJECTIONS; RANIBIZUMAB; TRIAMCINOLONE; HYPERTENSION; PEGAPTANIB; NEEDLES; IOP;
D O I
10.1016/j.ajo.2014.04.029
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE: To determine the intravitreal anti-vascular endothelial growth factor (VEGF) injection techniques and preferences within the retinal community and to identify potential factors associated with the development of sustained intraocular pressure (IOP) elevation in patients treated with intravitreal anti-VEGF therapy for neovascular age-related macular degeneration (AMD). DESIGN: Cross-sectional physician survey. METHODS: Five hundred and thirty retina specialists spanning both private and academic practices were surveyed regarding current anti-VEGF intravitreal injection protocols, including the anti-VEGF drug of choice, needle gauge, injection volume, injection technique, and self-reported prevalence of sustained IOP elevation. Multivariate logistic regressions were performed to assess the potential influence of these factors on long-term IOP. RESULTS: Two hundred ninety-two specialists (55%) reported believing that intravitreal anti-VEGF therapy may cause sustained IOP elevation. Of these responses, the most common reported prevalence was 1%-2% (48%), followed by 3%-5% (34%). There was no relationship between the frequency of sustained IOP elevation and anti-VEGF drug of choice. Physicians who injected greater than 0.05 cc in less than 1 second were 5.56 times more likely to observe a high frequency of sustained IOP elevation (P = .006, 95% CI 1.64-18.89). CONCLUSIONS: Based on physician survey data, serial anti-VEGF injections using higher injection volumes with a rapid injection technique may potentially lead to sustained IOP elevation. The underlying mechanism for this complication may be injury to the trabecular meshwork resulting from rapid elevations in IOP. Further investigation of the relationship between injection techniques and sustained IOP elevation in the form of retrospective or prospective clinical studies is warranted. ((C) 2014 by Elsevier Inc. All rights reserved.)
引用
收藏
页码:319 / 327
页数:9
相关论文
共 27 条
[1]   Incidence and Management of Elevated Intraocular Pressure with Antivascular Endothelial Growth Factor Agents [J].
Abedi, Gelareh ;
Adelman, Ron A. ;
Salim, Sarwat .
SEMINARS IN OPHTHALMOLOGY, 2013, 28 (03) :126-130
[2]   Persistent Ocular Hypertension Following Intravitreal Bevacizumab and Ranibizumab Injections [J].
Adelman, Ron A. ;
Zheng, Qi ;
Mayer, Hylton R. .
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2010, 26 (01) :105-110
[3]  
AIELLO LP, 2004, RETINA, V24, P3
[4]   Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab [J].
Bakri, S. J. ;
Pulido, J. S. ;
McCannel, C. A. ;
Hodge, D. O. ;
Diehl, N. ;
Hillemeier, J. .
EYE, 2009, 23 (01) :181-185
[5]   SUSTAINED ELEVATED INTRAOCULAR PRESSURES AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, RANIBIZUMAB, AND PEGAPTANIB [J].
Choi, Daniel Y. ;
Ortube, Maria Carolina ;
Mccannel, Colin A. ;
Sarraf, David ;
Hubschman, Jean-Pierre ;
Mccannel, Tara A. ;
Gorin, Michael B. .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2011, 31 (06) :1028-1035
[6]   Variations in intraocular pressure (IOP) and necessity for paracentesis following intravitreal triamcinolone injection [J].
Dwinger, MC ;
Pieper-Bodeewes, I ;
Eter, N ;
Holz, FG .
KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2005, 222 (08) :638-642
[7]   Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents [J].
Good, Travis J. ;
Kimura, Alan E. ;
Mandava, Naresh ;
Kahook, Malik Y. .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2011, 95 (08) :1111-1114
[8]  
Gregori NZ, J GLAUCOMA
[9]   INFLUENCE OF AXIAL LENGTH AND POSTINJECTION REFLUX ON SUSTAINED INTRAOCULAR PRESSURE ELEVATION AS A RESULT OF INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY [J].
Hoang, Quan V. ;
Jung, Jesse J. ;
Mrejen, Sarah ;
Freund, K. Bailey .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2014, 34 (03) :519-524
[10]   CLINICAL PREDICTORS OF SUSTAINED INTRAOCULAR PRESSURE ELEVATION DUE TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY [J].
Hoang, Quan V. ;
Tsuang, Angela J. ;
Gelman, Rony ;
Mendonca, Luis S. ;
Della Torre, Kara E. ;
Jung, Jesse J. ;
Freund, K. Bailey .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2013, 33 (01) :179-187